When will Platinib be launched in India?

As of now, the Indian version of Pralsetinib (Pralsetinib) original drug or generic drug has not been approved for marketing. The time a drug takes to market depends on a variety of factors, including the progress of clinical trials, the approval process by drug regulators, and the pharmaceutical company's plans. Platinib is an antineoplastic agent and inhibitor of multiple receptor tyrosine kinases, including wild-type and rearranged during transfection (RET) isoforms.

Platinib is designated as an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment ofJAK1/2-positive or TRKC-positive non-small cell lung cancer, medullary thyroid cancer, and thyroid cancer. Platinib can be used to treat advanced or metastatic RET mutation-positive medullary thyroid cancer and RET fusion-positive thyroid cancer (suitable for such treatment) in adult and pediatric patients 12 years of age or older who require systemic therapy. Confirmation that RET fusion is necessary before starting treatment. In clinical studies, the presence of RET fusions is determined by next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), or other tests.

The original drug Platinib has been launched in China, but it has not yet passed the relevant policies for inclusion in medical insurance. The price of 120 pills per box may be around 60,000 yuan. The price of the European version of Platinib's original drug sold overseas may be around RMB 40,000 per box of 60 pills, and the U.S. version may be priced around RMB 150,000 per box (the price may fluctuate due to exchange rates), which is expensive. There are also generic Platinib drugs available for sale overseas. The ingredients of the drug are basically the same as those of the original drug at home and abroad. The price of 120 pills per box may be more than RMB 4,000 (the price may fluctuate due to the exchange rate).